Related Experiment Video
Updated: Jul 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
MYBPC3 gene variations in hypertrophic cardiomyopathy patients in India
Reena R Tanjore1, Advithi Rangaraju, P G Kerkar
1Department of Genetics, Osmania University, Jamai Osmania PO, Hyderabad, Andhra Pradesh, India.
Insights
This study identified a novel frameshift mutation in the MYBPC3 gene in Indian patients with hypertrophic cardiomyopathy (HCM). This mutation leads to a truncated protein, offering new insights into HCM pathogenesis and genetic screening relevance in India.
Area of Science:
- Genetics
- Cardiology
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is an inherited autosomal dominant disorder affecting cardiac muscle.
- Mutations in the MYBPC3 gene are a significant cause of HCM, accounting for 15% of cases.
- Cardiac myosin-binding protein C (MyBPC) is crucial in heart muscle function.
Purpose of the Study:
- To screen specific exons (16, 18, 19, 22, 24, 28, 30, 31, 34) of the MYBPC3 gene in Indian patients diagnosed with HCM.
- To identify novel mutations and genetic variations within the MYBPC3 gene associated with HCM in the Indian population.
Main Methods:
- Genomic DNA was isolated from 95 HCM patients and 60 controls from CARE Hospital, India.
- Polymerase chain reaction (PCR) and single-stranded conformational polymorphism (SSCP) analysis were employed to screen targeted MYBPC3 gene exons.
Main Results:
- A novel frameshift mutation (D570fs) was discovered in exon 19 of the MYBPC3 gene.
- A novel single nucleotide polymorphism (SNP) was identified in codon 1093 of exon 31 (GGC/GGT).
- Seven known intronic SNPs and one known missense mutation (D770N) were also observed in the study population.
Conclusions:
- The novel D570fs mutation likely results in a truncated MyBPC protein, potentially via nonsense-mediated decay, impacting myosin and titin binding.
- The novel synonymous SNP in exon 31 may influence translation efficiency through altered codon-anticodon interactions.
- MYBPC3 gene screening is clinically relevant for diagnosing and understanding HCM in the Indian population.
Background:
Hypertrophic cardiomyopathy (HCM) is a complex cardiac muscular disorder, inherited as an autosomal dominant disease with variable penetrance. Cardiac myosin-binding protein C (MyBPC) is the predominant myosin-binding protein isoform in the heart muscle. One hundred forty-seven mutations have been detected in MYBPC3, accounting for 15% of all HCM cases.
Objective:
To screen exons 16, 18, 19, 22, 24, 28, 30, 31 and 34 in the MYBPC3 gene in Indian HCM patients.
Methods:
Sixty control and 95 HCM samples were collected from cardiology units of the CARE Hospital (Nampally, Banjara Hills, Secunderabad, India) for genomic DNA isolation followed by polymerase chain reaction and single-stranded conformational polymorphism analysis.
Results:
Screening of the exons revealed two variations - one novel frame shift mutation in exon 19 at the nucleotide position 11577-11578 and one novel single nucleotide polymorphism (SNP) in codon 1093 of exon 31, coding for glycine with a C>T transition (GGC/GGT), in addition to the seven known SNPs mainly in the intronic region and one known missense mutation D770N in this population.
Conclusion:
The novel frame shift mutation identified in exon 19, D570fs, with the insertion of an adenine residue in codon 570 coding for aspartate, results in a premature termination codon that produces a truncated protein lacking myosin- and titin-binding sites, explaining the role of the nonsense-mediated decay pathway. A novel SNP identified in codon 1093 of exon 31 was found to be a synonymous codon, which may have a regulatory effect at the translational level, attributing to affinity differences between codon-anticodon interactions. The screening of this gene may be relevant in the Indian context.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy

